Miles for Migraine, a registered 501(c)(3) non-profit, may be more known for the running events hosted across the country, but the organization will do more to promote education in March. In a continued effort to increase awareness and education, Miles for Migraine is hosting Migraine & Headache Education Day on Saturday, March 25, 2017 near Philadelphia. The event is an opportunity to meet others in the migraine and headache community for a day of learning. The work of Miles for Migraine was previously featured in HeadWise.

A preliminary study presented at the American Heart Association’s Scientific Sessions 2016 shows women with migraine may be more likely to suffer a stroke. This is not the first time migraine and stroke have been linked. Earlier in 2016, a study was presented at the American Stroke Association’s International Stroke Conference and revealed that migraine with aura doubles an individual’s likelihood of an ischemic stroke.

The National Headache Foundation is proud to again be participating in Headache on the Hill, an annual congressional advocacy event. Headache on the Hill participants visit the offices of approximately 130 members of Congress to raise issues on behalf of those with disabling headache and migraine, including the lack of research and stigma surrounding these diseases. Participants include physicians, researchers, as well as patients.

Connections between Migraine and Ehlers-Danlos syndrome (EDS) have been identified for several years. In 2011, a preliminary study published in Cephalalgia and led by current National Headache Foundation President, Vincent Martin, MD, suggested EDS is associated with increased disability, frequency, and prevalence of migraine in females.

Results from a Novartis Phase II study continue to show promise for a new class of chronic migraine prevention drugs, anti-calcitonin gene-related-peptide (CGRP) drugs. The study, which was presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland, demonstrated a significant reduction in monthly migraine days compared to placebo.